Skip to main content
Signal8
Launch Terminal

INSULET CORP (PODD)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Medical - Devices

Insulet Corp. logo

Insulet Corp.

NASDAQ:PODDHealthcare
-1.85%$149.68
AH$149.68+0.00%vs close
Mkt Cap$10.38B
Float69.1M
O/S69.35M
Vol
$ Vol
RVOL
Inst Own-
SI8.2%
Earnings
Dilution
Insulet Corp. logoNASDAQ:PODD$149.68-1.85%
Phase Distribution
23 lead-sponsored trials·6 active·17 completed
Not applicable23
(9 more as collaborator)
Status Overview
Recruiting5
Active, not recruiting1
Completed17

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
  • Not applicable
    Completed

    Insulet Artificial Pancreas Early Feasibility Study

    Insulet Artificial Pancreas (AP) System

    Type 1 Diabetes

    Enrollment
    59
    Start
    Sep 2016
    Primary Completion
    Feb 2017
    Completion
    Mar 2017
    NCT02897557
  • Not applicable
    Completed

    Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)

    Insulet AP (artificial pancreas) System

    Type 1 Diabetes Mellitus

    Enrollment
    24
    Start
    Mar 2017
    Primary Completion
    Apr 2017
    Completion
    Apr 2017
    NCT03064906
  • Not applicable
    Completed

    Insulet Artificial Pancreas Free-Living IDE3

    Insulet automated glucose control system

    Type1 Diabetes Mellitus

    Enrollment
    120
    Start
    Feb 2019
    Primary Completion
    May 2019
    Completion
    May 2019
    NCT03216460
  • Not applicable
    Completed

    Prepivotal Omnipod Horizon™ Automated Glucose Control System

    Omnipod Horizon™ Automated Glucose Control System

    Type 1 Diabetes Mellitus

    Enrollment
    36
    Start
    Dec 2019
    Primary Completion
    Jan 2020
    Completion
    Jan 2020
    NCT04176731
  • Not applicable
    Completed

    Pivotal Omnipod Horizon™ Automated Glucose Control System

    Omnipod Horizon™ Automated Glucose Control System

    Type 1 Diabetes Mellitus

    Enrollment
    240
    Start
    Dec 2019
    Primary Completion
    Jul 2020
    Completion
    Apr 2022
    NCT04196140
  • Not applicable
    Completed

    Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study

    Omnipod Horizon™ Automated Glucose Control System

    Type 1 Diabetes

    Enrollment
    25
    Start
    Jun 2020
    Primary Completion
    Sep 2020
    Completion
    Sep 2020
    NCT04320069
  • Not applicable
    Completed

    Omnipod Horizon™ Automated Glucose Control System Preschool Cohort

    Omnipod Horizon™ Automated Glucose Control System

    Type 1 Diabetes Mellitus

    Enrollment
    80
    Start
    Sep 2020
    Primary Completion
    Jan 2022
    Completion
    Oct 2022
    NCT04476472
  • Not applicable
    Completed

    Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes

    Omnipod 5 Automated Insulin Delivery System

    Type 2 Diabetes Mellitus

    Enrollment
    25
    Start
    Nov 2020
    Primary Completion
    Mar 2022
    Completion
    Mar 2022
    NCT04617795
  • Not applicable
    Completed

    Omnipod 5 System Compared to Pump Therapy

    Omnipod 5 System

    Type 1 Diabetes

    Enrollment
    196
    Start
    Jul 2022
    Primary Completion
    Sep 2023
    Completion
    Jan 2025
    NCT05409131
  • Not applicable
    Completed

    OP5-005 Using Omnipod 5 in Adults With Type 2

    Omnipod 5 Automated Glucose Control System

    Type2 Diabetes

    Enrollment
    343
    Start
    Apr 2023
    Primary Completion
    Mar 2024
    Completion
    Mar 2024
    NCT05815342
  • Not applicable
    Completed

    Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults

    Omnipod 5 System

    Diabetes Mellitus, Type 1

    Enrollment
    189
    Start
    Sep 2023
    Primary Completion
    Aug 2024
    Completion
    Feb 2026
    NCT05923827
  • Observational
    Recruiting

    Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes

    Omnipod 5

    Type 1 Diabetes

    Enrollment
    2,200
    Start
    Sep 2023
    Primary Completion
    Jun 2027est.
    Completion
    Sep 2028est.
    NCT06144554
  • Not applicable
    Completed

    Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes

    Omnipod 5 Automated Glucose Control System

    Diabetes Mellitus

    Enrollment
    20
    Start
    Sep 2023
    Primary Completion
    Jan 2024
    Completion
    Jan 2024
    NCT06181721
  • Not applicable
    Completed

    SmartAdjust 2.0 System With Type 1 and Type 2 Diabetes

    Omnipod 5 SA2.0 System

    Diabetes Mellitus

    Enrollment
    48
    Start
    Jul 2024
    Primary Completion
    Sep 2025
    Completion
    Sep 2025
    NCT06547918
  • Not applicable
    Completed

    Omnipod® SmartAdjust 2.0 System Compared to the Omnipod® 5 System in Individuals With Type 1 or Type 2 Diabetes

    Omnipod 5 SmartAdjust 2.0 System, Omnipod 5 System

    Diabetes Mellitus, Type 1, Type 2

    Enrollment
    132
    Start
    Mar 2025
    Primary Completion
    Nov 2025
    Completion
    Nov 2025
    NCT06865989
  • Observational
    Active, not recruiting

    French Prospective Multicentric Study in Real World

    Omnipod 5

    Diabetes, Diabetes Mellitus +1

    Enrollment
    304
    Start
    Jul 2025
    Primary Completion
    Jul 2027est.
    Completion
    Jul 2027est.
    NCT07039942
  • Not applicable
    Completed

    Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Adults With Type 2 Diabetes

    Omnipod M system

    Diabetes Mellitus

    Enrollment
    48
    Start
    Jul 2025
    Primary Completion
    May 2026
    Completion
    May 2026
    NCT07039981
  • Not applicable
    Completed

    Simplified Onboarding in Adults With Type 2 Diabetes

    Active Comparator: Omnipod M System with lower starting dose, Active Comparator: Omnipod M System with higher starting dose

    Type 2 Diabetes Mellitus

    Enrollment
    56
    Start
    Jul 2025
    Primary Completion
    Jan 2026
    Completion
    Jan 2026
    NCT07070830
  • Not applicable
    Completed

    An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes

    Omnipod M system

    Type 2 Diabetes Mellitus

    Enrollment
    40
    Start
    Dec 2025
    Primary Completion
    Mar 2026
    Completion
    Mar 2026
    NCT07276776
  • Observational
    Recruiting

    Omnipod-5 A French Prospective Multicentric Study in Real World (Optimal-B)

    Omnipod 5

    Diabetes, Type 1 Diabetes +1

    Enrollment
    152
    Start
    Mar 2026
    Primary Completion
    Nov 2027est.
    Completion
    Nov 2027est.
    NCT07317102
  • Not applicable
    Recruiting

    Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

    Device: Omnipod M System with study CGM, Standard Therapy plus study CGM

    Type 2 Diabetes Mellitus

    Enrollment
    350
    Start
    Apr 2026
    Primary Completion
    Dec 2026est.
    Completion
    Sep 2027est.
    NCT07521475
  • Not applicable
    Recruiting

    Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

    Omnipod 5 System, Omnipod 6 System

    Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus

    Enrollment
    200
    Start
    May 2026
    Primary Completion
    Feb 2027est.
    Completion
    Mar 2027est.
    NCT07579702
  • Not applicable
    Recruiting

    Evaluating Glucose Control Using a Next-Generation AID Algorithm in Individuals With T1D

    Omnipod M System, Omnipod S

    Type 1 Diabetes, Type 1 Diabetes Mellitus +1

    Enrollment
    80
    Start
    May 2026
    Primary Completion
    Dec 2026est.
    Completion
    Feb 2027est.
    NCT07593625
Search ClinicalTrials.gov for “Insulet”